Ruxolitinib Resolves Severe Diarrhea Following BCMA-Targeted CAR T-Cell Therapy

The treatment of relapsed or refractory multiple myeloma has been significantly altered by the introduction of chimeric antigen receptor (CAR) T-cell therapies, which genetically engineer a patient's own immune cells to recognize and destroy malignant plasma cells [1]. Despite their efficacy, these treatments are frequently complicated by systemic toxicities, most notably cytokine release syndrome (a systemic inflammatory response) and neurotoxicity [2, 3]. Recently, clinicians have identified a distinct and severe complication known as immune effector cell-associated enterocolitis, characterized by profound, watery diarrhea that often resists standard management [4]. This condition frequently results in extreme weight loss, a requirement for total parenteral nutrition (intravenous feeding), and high mortality rates [4]. Because this syndrome often fails to respond to conventional corticosteroids, there is an urgent clinical need for targeted immunosuppressive strategies [3, 4]. A recent study investigates a specific pharmacological approach to resolve this life-threatening gastrointestinal toxicity.